Envestnet Asset Management Inc Reata Pharmaceuticals Inc Transaction History

Envestnet Asset Management Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	BUY	$79.22 - $105.37 $237,105 - $315,372	2,993 Added 71.55%	7,176 $731,000
Q1 2023 May 11, 2023	SELL	$30.85 - $93.17 $149,931 - $452,806	-4,860 Reduced 53.74%	4,183 $380,000
Q4 2022 Feb 07, 2023	BUY	$22.15 - $42.11 $200,302 - $380,800	9,043 New	9,043 $343,000
Q4 2021 Feb 04, 2022	SELL	$25.61 - $110.96 $67,251 - $291,380	-2,626 Closed	0 $0
Q3 2021 Oct 07, 2021	SELL	$100.0 - $143.02 $700 - $1,001	-7 Reduced 0.27%	2,626 $264,000
Q2 2021 Aug 04, 2021	SELL	$78.27 - $151.29 $7,670 - $14,826	-98 Reduced 3.59%	2,633 $373,000
Q1 2021 May 04, 2021	BUY	$94.25 - $132.81 $36,192 - $50,999	384 Added 16.36%	2,731 $272,000
Q4 2020 Feb 02, 2021	BUY	$102.03 - $184.62 $239,464 - $433,303	2,347 New	2,347 $290,000
Q3 2020 Oct 09, 2020	SELL	$93.53 - $163.34 $161,993 - $282,904	-1,732 Closed	0 $0
Q2 2020 Jul 08, 2020	BUY	$126.3 - $176.56 $218,751 - $305,801	1,732 New	1,732 $270,000
Q1 2020 Apr 23, 2020	SELL	$124.16 - $247.74 $209,830 - $418,680	-1,690 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$74.57 - $217.92 $126,023 - $368,284	1,690 New	1,690 $345,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Envestnet Asset Management Inc with notifications on news.